Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.
Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Existing medicines could offer a new way to treat inflammatory skin conditions, researchers at Melbourne's Walter and Eliza Hall Institute and the Royal Melbourne Hospital have revealed.
Wanting a tan or simply enjoying the outdoors during the summer can expose skin to the effects of ultraviolet rays- a problem complicated for people taking certain medications, warns a Harris Health System expert.
The immunotherapy nivolumab is kinder than chemotherapy for people with advanced head and neck cancer - easing many of the negative effects of the disease on patients' quality of life.
Patients suffering from rheumatoid arthritis are treated for around six months with the standard anti-rheumatic agent methotrexate, to which many patients respond very well.
The results of a study presented today at the Annual European Congress of Rheumatology 2017 have confirmed that Fluorescence Optical Imaging, a technique used to visualize inflammation in arthritic joints, is as effective as ultrasound with Power Doppler (US / PD) at monitoring response to treatment in juvenile idiopathic arthritis.
Being able to monitor drug concentration in the blood of a patient is an important aspect of any pharmaceutical treatment. However, this requires equipment and facilities that are often missing from field healthcare in developing countries, but also inhibits the quality of life for patients elsewhere.
BSR and the RCGP have today launched a joint Quality Improvement project to improve care for people living with inflammatory arthritis.
Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better - and had fewer adverse outcomes - than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by the National Eye Institute.
A clinical trial funded by Arthritis Research UK and the National Institute for Health Research led by professors from the Universities of Liverpool and Bristol has discovered a drug combination that could help thousands of children with arthritis.
This latest guidance sets out evidence based recommendations for clinicians prescribing synthetic, non-biologic, anti-rheumatic drugs to tackle multisystem rheumatic conditions.
Current treatments for rheumatoid arthritis relieve the inflammation that leads to joint destruction, but the immunologic defect that triggers the inflammation persists to cause relapses, according to research conducted at NYU Langone Medical Center and the University of Pittsburgh.
Two new clinical trials for pediatric brain cancer have begun at The University of Texas Health Science Center at Houston and Children's Memorial Hermann Hospital.
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.
Macrophages are frontline cells in our immune system. They detect microbial invaders and also tissue injury and then mount an appropriate response needed to clear the infection and repair the damaged tissue.
More than 1,000 medications, with acetaminophen being the most common, have been associated with drug-induced liver injury.
A study finds that smoking or being overweight makes it more difficult for patients with rheumatoid arthritis to achieve optimal control of inflammation and symptoms, despite standard of care treatment.
CreakyJoints, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy, and patient-centered research, today announced the forthcoming publication of “A Patient’s Guide to Living with Rheumatoid Arthritis.”
Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.
A group of researchers from Columbia University, Rutgers University, and institutions in Europe and Japan have identified genomic alterations in pediatric relapsed acute lymphoblastic leukemia (ALL) that cause both therapy resistance and improved clinical response to multi-agent chemotherapy treatment.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the six months ended June 30, 2016 and updates on its drug development programs.